{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:36:55Z","timestamp":1786534615403,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72404205"],"award-info":[{"award-number":["72404205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Project of the National Social Science Fund of China","award":["25&ZD143"],"award-info":[{"award-number":["25&ZD143"]}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Plan Project","doi-asserted-by":"crossref","award":["24ZXYXSY00090"],"award-info":[{"award-number":["24ZXYXSY00090"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"DOI":"10.1186\/s12955-026-02560-6","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:54:36Z","timestamp":1780685676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life and its associated factors among patients with neuromyelitis optica spectrum disorder in China: a questionnaire survey analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wenxuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"7","key":"2560_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","volume":"21","author":"L PANDIT","year":"2015","unstructured":"PANDIT L, ASGARI N, APIWATTANAKUL M, et al. Demographic and clinical features of neuromyelitis optica: A review [J]. Mult Scler. 2015;21(7):845\u201353.","journal-title":"Mult Scler"},{"issue":"2","key":"2560_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V PAPP","year":"2021","unstructured":"PAPP V, MAGYARI M, AKTAS O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review [J]. Neurology. 2021;96(2):59\u201377.","journal-title":"Neurology"},{"issue":"2","key":"2560_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"B WINGERCHUK D M, BANWELL","year":"2015","unstructured":"WINGERCHUK D M, BANWELL B. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders [J]. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"8","key":"2560_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","volume":"88","author":"W BUKHARI","year":"2017","unstructured":"BUKHARI W, PRAIN K M WATERSP, et al. Incidence and prevalence of NMOSD in Australia and New Zealand [J]. J Neurol Neurosurg Psychiatry. 2017;88(8):632\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2560_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ana.24617","volume":"79","author":"P FLANAGAN E P, CABRE","year":"2016","unstructured":"FLANAGAN E P, CABRE P, WEINSHENKER B G, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum [J]. Ann Neurol. 2016;79(5):775\u201383.","journal-title":"Ann Neurol"},{"key":"2560_CR6","first-page":"100021","volume":"2","author":"DC TIAN","year":"2020","unstructured":"TIAN DC, LI Z, YUAN M, et al. Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study [J]. Lancet Reg Health West Pac. 2020;2:100021.","journal-title":"Lancet Reg Health West Pac"},{"key":"2560_CR7","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.msard.2020.102542","volume":"46","author":"W HUANG","year":"2020","unstructured":"HUANG W, ZHANGBAO J, CHANG X, et al. Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience [J]. Mult Scler Relat Disord. 2020;46:102542.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"2560_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","volume":"17","author":"S HUGHES D A, BOURKE","year":"2022","unstructured":"HUGHES D A, BOURKE S. Health utilities and costs for neuromyelitis optica spectrum disorder [J]. Orphanet J Rare Dis. 2022;17(1):159.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2560_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","volume":"11","author":"F KNAPP R K, HARDTSTOCK","year":"2022","unstructured":"KNAPP R K, HARDTSTOCK F, WILKE T, et al. Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data [J]. Neurol Ther. 2022;11(1):247\u201363.","journal-title":"Neurol Ther"},{"issue":"4","key":"2560_CR10","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","volume":"6","author":"J BEEKMAN","year":"2019","unstructured":"BEEKMAN J, KEISLER A, PEDRAZA O, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life [J]. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e580.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2560_CR11","doi-asserted-by":"publisher","first-page":"117546","DOI":"10.1016\/j.jns.2021.117546","volume":"428","author":"K FUJIHARA","year":"2021","unstructured":"FUJIHARA K, HATTORI S, KLEITER I, et al. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life [J]. J Neurol Sci. 2021;428:117546.","journal-title":"J Neurol Sci"},{"key":"2560_CR12","doi-asserted-by":"publisher","first-page":"102711","DOI":"10.1016\/j.msard.2020.102711","volume":"48","author":"Y YALACHKOV","year":"2021","unstructured":"YALACHKOV Y, SOYDA\u015e D. Impact of psychiatric distress and physical disability on quality of life in neuromyelitis optica spectrum disorder and chronic autoimmune demyelinating polyneuropathies [J]. Mult Scler Relat Disord. 2021;48:102711.","journal-title":"Mult Scler Relat Disord"},{"key":"2560_CR13","doi-asserted-by":"publisher","first-page":"1099376","DOI":"10.3389\/fneur.2023.1099376","volume":"14","author":"A BERTHELE","year":"2023","unstructured":"BERTHELE A, LEVY M, WINGERCHUK D M, et al. A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder [J]. Front Neurol. 2023;14:1099376.","journal-title":"Front Neurol"},{"issue":"11","key":"2560_CR14","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","volume":"98","author":"MW H\u00fcMMERT","year":"2022","unstructured":"H\u00fcMMERT MW, SCH\u00f6PPE LM, BELLMANN-STROBL J, et al. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE(NMO) Study [J]. Neurology. 2022;98(11):e1184\u201396.","journal-title":"Neurology"},{"key":"2560_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","volume":"293","author":"Z SHI","year":"2016","unstructured":"SHI Z, CHEN H, LIAN Z, et al. Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression [J]. J Neuroimmunol. 2016;293:54\u20138.","journal-title":"J Neuroimmunol"},{"key":"2560_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.msard.2018.07.004","volume":"24","author":"S SIRITHO","year":"2018","unstructured":"SIRITHO S, THAVORNCHAROENSAP M, CHANATITTARAT C, et al. Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand [J]. Mult Scler Relat Disord. 2018;24:151\u20136.","journal-title":"Mult Scler Relat Disord"},{"key":"2560_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.msard.2018.04.009","volume":"22","author":"M BARZEGAR","year":"2018","unstructured":"BARZEGAR M, BADIHIAN S, MIRMOSAYYEB O, et al. Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran [J]. Mult Scler Relat Disord. 2018;22:161\u20135.","journal-title":"Mult Scler Relat Disord"},{"key":"2560_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2019.04.008","volume":"32","author":"M BARZEGAR","year":"2019","unstructured":"BARZEGAR M, SADEGHI BAHMANI D, NEHZAT N, et al. Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls [J]. Mult Scler Relat Disord. 2019;32:81\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"2560_CR19","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.msard.2022.103647","volume":"59","author":"PA CARNERO CONTENTTI E, EIZAGUIRRE M B","year":"2022","unstructured":"CARNERO CONTENTTI E, EIZAGUIRRE M B, L\u00f3PEZ PA, et al. Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort [J]. Mult Scler Relat Disord. 2022;59:103647.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"2560_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40120-022-00356-6","volume":"11","author":"R MECA-LALLANA J E, G\u00f3MEZ-BALLESTEROS","year":"2022","unstructured":"MECA-LALLANA J E, G\u00f3MEZ-BALLESTEROS R, P\u00e9REZ-MIRALLES F, et al. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients\u2019 Perspective: An Observational Cross-Sectional Study [J]. Neurol Ther. 2022;11(3):1101\u201316.","journal-title":"Neurol Ther"},{"issue":"10","key":"2560_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M HERDMAN","year":"2011","unstructured":"HERDMAN M, GUDEX C, LLOYD A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) [J]. Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"4","key":"2560_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N LUO","year":"2017","unstructured":"LUO N, LIU G, LI M, et al. Estimating an EQ-5D-5L Value Set for China [J]. Value Health. 2017;20(4):662\u20139.","journal-title":"Value Health"},{"issue":"4","key":"2560_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40258-022-00715-2","volume":"20","author":"S XIE","year":"2022","unstructured":"XIE S, WU J, XIE F. Population Norms for SF-6Dv2 and EQ-5D-5L in China [J]. Appl Health Econ Health Policy. 2022;20(4):573\u201385.","journal-title":"Appl Health Econ Health Policy"},{"key":"2560_CR24","doi-asserted-by":"publisher","first-page":"103445","DOI":"10.1016\/j.msard.2021.103445","volume":"57","author":"T WANG","year":"2022","unstructured":"WANG T, RUAN H, FAN P, et al. Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression [J]. Mult Scler Relat Disord. 2022;57:103445.","journal-title":"Mult Scler Relat Disord"},{"issue":"1s","key":"2560_CR25","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.chest.2020.03.012","volume":"158","author":"X WANG","year":"2020","unstructured":"WANG X, Cross-Sectional Studies CHENGZ. Strengths, Weaknesses, and Recommendations [J]. Chest. 2020;158(1s):S65\u201371.","journal-title":"Chest"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-026-02560-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:03:54Z","timestamp":1786532634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12955-026-02560-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2560"],"URL":"https:\/\/doi.org\/10.1186\/s12955-026-02560-6","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Academic Ethics Committee at Tianjin University on April 12, 2024 (TJUE-2024-269) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Participants were informed about their freedom of refusal. Anonymity and confidentiality were maintained throughout the research process.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","label":"Role of the funder\/sponsor","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}